The Progress of New Targets of Anti-HIV and Its Inhibitors
Author:
Wu Ke Z.,Li Ai X.
Publisher
Springer Netherlands
Reference42 articles.
1. Aiamkitsumrit B, Dampier W, Martin-Garcia J, Nonnemacher MR, Pirrone V, Ivanova T, Zhong W, Kilareski E, Aldigun H, Frantz B, Rimbey M, Wojno A, Passic S, Williams JW, Shah S, Blakey B, Parikh N, Jacobson JM, Moldover B, Wigdahl B. Defining Differential Genetic Signatures in CXCR4- and the CCR5-Utilizing HIV-1 Co-Linear Sequences PloS One 2014; 9: 1–22 doi: 10.1371/journal.pone.0107389 . PMID:25265194 2. Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L. Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol. 2011;85:9039–50. doi: 10.1128/JVI.02675-10 . PMID:21697467 3. Anderson JS. Using TRIM5α as an HIV therapeutic: the alpha gene? Expert Opin Biol Ther. 2013;13:1029–38. doi: 10.1517/14712598.2013.779251 . PMID:23480791 4. Berro R, Klasse PJ, Jakobsen MR, Gorry PR, Moore JP, Sanders RW. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology 2012; 427: 158–165 doi:10.1016/j.virol.2012.02.006. PMID:22424737 5. Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk DI, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry. 2004;43:1928–38. doi: 10.1021/bi035088i . PMID:14967033
|
|